Press Releases

02.12.2021
DGAP-Media

Aladdin Healthcare Announces OTCQB listing and a precursor for its transformation that will include acquisitions in the digital healthcare and blockchain arena

December 2, 2021 – London, United Kingdom – Aladdin Healthcare (“Aladdin” or the “Company”) (NMI: XTRA, ALDNF: OTCQB), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, announces that it has gained approval from OTC Markets Group to have the company’s shares quoted on the OTCQB market. The company’s shares will be traded under the symbol ALDNF.

Value Drivers and Forward-Looking Plans

Along with the new US stock quotation, Aladdin Healthcare is re-positioning its business through merger or acquisition opportunities to transform its commercial viability and in turn monetise its AI and blockchain technologies. The Company’s intention is to control its entire supply chain through owning its own healthcare network, which will consist of doctors, patients and their data.

To build something of significance the Company is looking to develop one of the largest blockchain driven healthcare patient networks in Asia (ex- China). Targeting 100 million patients on its network over the medium term. The Company is actively identifying targets and aims to announce its first acquisition in the months ahead.

Post its first acquisition, the Company will then be in a position to distribute its variety of proprietary blood tests, COVID tests and other AI driven diagnostics in stages to millions of users within its network. As the ecosystem grows the Company will introduce a multitude of other third-party tests and applications that will drive revenue and growth. Culminating in billions of valuable medical data inputs for multiple diseases, thereby opening significant opportunity for the global pharmaceutical industry to collaborate with Aladdin.

In parallel, Aladdin through its US quote will seek to revalue its business and aim to raise capital in the US to support its acquisitions and working capital.

“By adding this US quote, we are now moving into the world’s best capital market for healthcare technology, whilst executing our global strategy to attract investment from North American based investors. ALDNF will provide Aladdin with access to a larger community for further strategic transactions. As a leading developer of AI healthcare diagnostics and drug discovery applications for age-related diseases, we see it as a great opportunity to present our business model and its growth prospects to investors who are attracted to innovative companies with rapid growth potential,” said Wade Menpes-Smith, CEO from Aladdin Healthcare Technologies SE.

About Aladdin Healthcare Technologies SE

Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330
Email: sh@crossalliance.de
www.crossalliance.de